PMID: 8440364Feb 1, 1993Paper

Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I--a randomized study. Myeloma Group of Western Sweden

European Journal of Haematology
M HjorthJ Westin

Abstract

From October 1983 until December 1988, 50 patients with asymptomatic multiple myeloma stage I were included in a prospective randomized multi-centre study comparing melphalan-prednisone (MP) therapy started at the time of diagnosis with deferred therapy where MP was started at the time of disease progression. Twenty-five patients were randomized to each group. The median time from diagnosis to start of therapy in the group with deferred therapy was 12 months. The reasons for starting therapy were increasing M-protein in 8 cases, symptomatic bone disease in 9 and anaemia in 5. In 2 cases, disease progression was complicated by vertebral fractures necessitating radiotherapy. Two patients in the group in which MP was started at the time of diagnosis developed acute leukaemia. No differences in response rate, response duration or survival were observed between the treatment groups. We conclude that in asymptomatic myeloma deferral of chemotherapy is feasible in well-informed and well-controlled patients but conveys no advantage in survival. In clinical practice the benefits of treatment deferral are to some extent outweighed by disease progression before start of treatment.

References

Aug 1, 1990·Cancer Genetics and Cytogenetics·S RödjerJ Westin
Jan 1, 1986·Acta Medica Scandinavica·U Axelsson
Aug 1, 1983·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S E SalmonD O Dixon
Jun 12, 1980·The New England Journal of Medicine·R A Kyle, P R Greipp

❮ Previous
Next ❯

Citations

Jul 6, 2000·Current Opinion in Hematology·N N Sjak-ShieJ R Berenson
Jun 12, 2002·Current Treatment Options in Oncology·Donna M Weber
Mar 6, 2003·Reviews in Clinical and Experimental Hematology·Robert A Kyle, S Vincent Rajkumar
Jan 22, 2003·The Cochrane Database of Systematic Reviews·Y HeB Djulbegovic
Aug 2, 2013·The New England Journal of Medicine·María-Victoria MateosJesús-F San Miguel
Feb 26, 2014·Leukemia & Lymphoma·Adewale FawoleIshmael Jaiyesimi
Sep 12, 2014·Current Opinion in Oncology·María-Victoria Mateos
Jun 14, 2016·American Journal of Hematology·S Vincent Rajkumar
Feb 20, 2016·Current Hematologic Malignancy Reports·Srinath SundararajanAmit Agarwal
Dec 8, 2015·Hematology·S Vincent Rajkumar
Nov 15, 2018·Blood Advances·María-Victoria Mateos, Verónica González-Calle
Feb 17, 1994·The New England Journal of Medicine·R Alexanian, M Dimopoulos
Nov 18, 2003·British Journal of Haematology·L RosiñolE Montserrat
Nov 21, 2008·European Journal of Haematology·Francesca PatriarcaAntonio Palumbo
Aug 7, 2008·Cancer·Pellegrino MustoUNKNOWN GIMEMA (Italian Group for Adult Hematologic Diseases)/Multiple Myeloma Working Party and the Italian Myeloma Network
Dec 23, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Joan BladéRobert A Kyle
Dec 17, 2009·The Cancer Journal·Sigurdur Yngvi KristinssonVincent S Rajkumar
Nov 26, 2010·Annual Review of Medicine·Jacob LaubachKenneth Anderson
Oct 12, 2013·European Journal of Haematology·Nishant TagejaOla Landgren
Aug 2, 2012·Nature Reviews. Clinical Oncology·S Vincent RajkumarJesus F San Miguel
Jan 3, 2014·Expert Review of Hematology·Saad Zafar Usmani
Nov 26, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Inhye E AhnOla Landgren
May 23, 2015·Expert Opinion on Orphan Drugs·Karma Z Salem, Irene M Ghobrial
Feb 28, 2016·The Oncologist·Jo CaersMonika Engelhardt
Jan 30, 2019·The Cancer Journal·Prashant Kapoor, S Vincent Rajkumar
Oct 28, 2019·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sagar LonialS Vincent Rajkumar
Jun 1, 1994·Journal of the American Geriatrics Society·M Gautier, H J Cohen
Aug 26, 1998·Scottish Medical Journal·R L Soutar
Jul 9, 2003·Immunological Reviews·Robert A Kyle, S Vincent Rajkumar
Jun 12, 2002·Current Treatment Options in Oncology·P R Greipp
Aug 12, 1999·British Journal of Haematology·F E LecouvetB C Vande Berg
Jun 7, 2008·The Journal of International Medical Research·J RedzepovicR Gust
Apr 18, 2006·Current Treatment Options in Oncology·Joan Bladé, Laura Rosiñol
Nov 2, 2007·Leukemia·K C AndersonUNKNOWN ASH/FDA Panel on Clinical Endpoints in Multiple Myeloma
Feb 6, 2009·The Annals of Pharmacotherapy·Ayman A SaadGerald M Higa
Oct 23, 2013·Blood·Angela DispenzieriShaji K Kumar
May 1, 2013·Leukemia Supplements·S Girnius, N C Munshi
Jul 30, 2015·British Journal of Haematology·Guy PrattJenny Bird

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.